The ECOG-ACRIN Cancer Research Group is dedicated to reducing the occurrence of cancer and improving the quality of life and survival in adults with cancer. The Group addresses a broad range of research goals in its clinical trials, which are medical research studies where people volunteer to test new scientific approaches.
Most ECOG-ACRIN cancer trials are treatment studies that involve people who have cancer. ECOG-ACRIN also leads trials focused on prevention, screening (checking for cancer or for conditions that may lead to cancer in people who have no symptoms), diagnosis, patient-reported outcomes, cancer care delivery, precision medicine, and survivorship.
Clinical trials contribute to the overall understanding of and progress against cancer. Many people treated for cancer are now living longer thanks to the knowledge gained through clinical trials.
Taking an active part in cancer clinical trials can be an empowering experience for people at risk of having cancer and those diagnosed with cancer. These trials will not only help them, but will help others as well.
An important benefit of participating in a clinical trial is the high level of patient care. Patients in cancer clinical trials are usually followed more closely by their doctors and nurses, which provides patients with a high-quality experience.
Depending upon the type of cancer treatment, trials are conducted in doctors’ offices, cancer centers, other medical centers, community hospitals and clinics, and veterans’ and military hospitals in cities and towns across the United States and around the world. Cancer clinical trials may include participants at one or two highly specialized centers or they may involve hundreds of locations at the same time.
Although patients are the only ones who can decide whether to take part in a cancer clinical trial, the doctor and the rest of the healthcare team are important and valuable sources of balanced information about the risks and benefits of participating in a clinical trial.
Please read the ECOG-ACRIN Disclaimer in its entirety before accessing any of the information in this section.